Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $163.53 billion. The enterprise value is $216.22 billion.
| Market Cap | 163.53B |
| Enterprise Value | 216.22B |
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | May 16, 2025 |
Share Statistics
Amgen has 537.20 million shares outstanding. The number of shares has increased by 0.56% in one year.
| Current Share Class | 537.20M |
| Shares Outstanding | 537.20M |
| Shares Change (YoY) | +0.56% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 79.08% |
| Float | 535.68M |
Valuation Ratios
The trailing PE ratio is 40.25 and the forward PE ratio is 14.74. Amgen's PEG ratio is 2.96.
| PE Ratio | 40.25 |
| Forward PE | 14.74 |
| PS Ratio | 5.05 |
| Forward PS | 4.66 |
| PB Ratio | 28.72 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.10 |
| P/OCF Ratio | 14.56 |
| PEG Ratio | 2.96 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.27, with an EV/FCF ratio of 20.80.
| EV / Earnings | 52.87 |
| EV / Sales | 6.47 |
| EV / EBITDA | 14.27 |
| EV / EBIT | 22.35 |
| EV / FCF | 20.80 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 10.36.
| Current Ratio | 1.26 |
| Quick Ratio | 0.84 |
| Debt / Equity | 10.36 |
| Debt / EBITDA | 3.96 |
| Debt / FCF | 5.86 |
| Interest Coverage | 2.64 |
Financial Efficiency
Return on equity (ROE) is 67.55% and return on invested capital (ROIC) is 8.74%.
| Return on Equity (ROE) | 67.55% |
| Return on Assets (ROA) | 6.40% |
| Return on Invested Capital (ROIC) | 8.74% |
| Return on Capital Employed (ROCE) | 14.08% |
| Revenue Per Employee | $1.19M |
| Profits Per Employee | $146,071 |
| Employee Count | 28,000 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Amgen has paid $519.00 million in taxes.
| Income Tax | 519.00M |
| Effective Tax Rate | 11.26% |
Stock Price Statistics
The stock price has increased by +10.63% in the last 52 weeks. The beta is 0.52, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +10.63% |
| 50-Day Moving Average | 298.38 |
| 200-Day Moving Average | 306.64 |
| Relative Strength Index (RSI) | 45.59 |
| Average Volume (20 Days) | 3,144,081 |
Short Selling Information
The latest short interest is 16.08 million, so 2.99% of the outstanding shares have been sold short.
| Short Interest | 16.08M |
| Short Previous Month | 12.74M |
| Short % of Shares Out | 2.99% |
| Short % of Float | 3.00% |
| Short Ratio (days to cover) | 5.00 |
Income Statement
In the last 12 months, Amgen had revenue of $33.42 billion and earned $4.09 billion in profits. Earnings per share was $7.56.
| Revenue | 33.42B |
| Gross Profit | 22.97B |
| Operating Income | 9.68B |
| Pretax Income | n/a |
| Net Income | 4.09B |
| EBITDA | 15.16B |
| EBIT | 9.68B |
| Earnings Per Share (EPS) | $7.56 |
Balance Sheet
The company has $11.97 billion in cash and $60.88 billion in debt, giving a net cash position of -$48.91 billion or -$91.04 per share.
| Cash & Cash Equivalents | 11.97B |
| Total Debt | 60.88B |
| Net Cash | -48.91B |
| Net Cash Per Share | -$91.04 |
| Equity (Book Value) | 5.88B |
| Book Value Per Share | 10.95 |
| Working Capital | 5.93B |
Cash Flow
In the last 12 months, operating cash flow was $11.49 billion and capital expenditures -$1.10 billion, giving a free cash flow of $10.39 billion.
| Operating Cash Flow | 11.49B |
| Capital Expenditures | -1.10B |
| Free Cash Flow | 10.39B |
| FCF Per Share | $19.35 |
Margins
Gross margin is 68.71%, with operating and profit margins of 28.95% and 12.24%.
| Gross Margin | 68.71% |
| Operating Margin | 28.95% |
| Pretax Margin | 13.79% |
| Profit Margin | 12.24% |
| EBITDA Margin | 45.35% |
| EBIT Margin | 28.95% |
| FCF Margin | 31.10% |
Dividends & Yields
This stock pays an annual dividend of $9.52, which amounts to a dividend yield of 3.13%.
| Dividend Per Share | $9.52 |
| Dividend Yield | 3.13% |
| Dividend Growth (YoY) | 5.71% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 125.93% |
| Buyback Yield | -0.56% |
| Shareholder Yield | 2.50% |
| Earnings Yield | 2.44% |
| FCF Yield | 6.21% |
Analyst Forecast
The average price target for Amgen is $323.26, which is 6.20% higher than the current price. The consensus rating is "Buy".
| Price Target | $323.26 |
| Price Target Difference | 6.20% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 2.90% |
| EPS Growth Forecast (5Y) | 26.33% |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.5 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.5 |
| Piotroski F-Score | 6 |